IRIS
CLERICO, ALDO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 61.877
EU - Europa 37.243
AS - Asia 21.437
SA - Sud America 3.691
Continente sconosciuto - Info sul continente non disponibili 449
AF - Africa 414
OC - Oceania 33
Totale 125.144
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 60.005
GB - Regno Unito 14.519
SG - Singapore 7.876
RU - Federazione Russa 6.679
CN - Cina 6.088
IT - Italia 4.826
UA - Ucraina 3.968
VN - Vietnam 3.132
BR - Brasile 2.963
DE - Germania 2.434
HK - Hong Kong 1.933
CA - Canada 1.271
SE - Svezia 975
FI - Finlandia 933
FR - Francia 870
DK - Danimarca 787
PL - Polonia 642
BD - Bangladesh 543
IN - India 376
IL - Israele 274
AR - Argentina 246
MX - Messico 206
IE - Irlanda 204
EU - Europa 202
ZA - Sudafrica 156
TR - Turchia 150
IQ - Iraq 146
ID - Indonesia 144
EC - Ecuador 115
JP - Giappone 100
VE - Venezuela 97
CO - Colombia 95
PK - Pakistan 94
NL - Olanda 88
ES - Italia 73
KR - Corea 68
SA - Arabia Saudita 68
CL - Cile 66
JM - Giamaica 65
UZ - Uzbekistan 61
MA - Marocco 56
MY - Malesia 53
CR - Costa Rica 46
PH - Filippine 45
TT - Trinidad e Tobago 41
RO - Romania 39
AE - Emirati Arabi Uniti 37
GT - Guatemala 36
HN - Honduras 36
NI - Nicaragua 35
PY - Paraguay 35
JO - Giordania 34
TN - Tunisia 34
KE - Kenya 33
LT - Lituania 33
UY - Uruguay 33
SV - El Salvador 32
EG - Egitto 30
NP - Nepal 29
PR - Porto Rico 29
AT - Austria 25
DZ - Algeria 25
AU - Australia 23
ET - Etiopia 21
GP - Guadalupe 21
PE - Perù 20
AZ - Azerbaigian 18
CW - ???statistics.table.value.countryCode.CW??? 18
SK - Slovacchia (Repubblica Slovacca) 18
IR - Iran 15
KZ - Kazakistan 15
PA - Panama 15
TH - Thailandia 15
OM - Oman 14
PT - Portogallo 14
TW - Taiwan 14
BO - Bolivia 13
RS - Serbia 13
AL - Albania 12
BH - Bahrain 12
BB - Barbados 11
CH - Svizzera 11
DO - Repubblica Dominicana 11
PS - Palestinian Territory 11
BE - Belgio 9
BY - Bielorussia 9
CZ - Repubblica Ceca 9
LB - Libano 9
CI - Costa d'Avorio 8
KW - Kuwait 8
NG - Nigeria 8
NZ - Nuova Zelanda 8
QA - Qatar 8
AM - Armenia 7
AO - Angola 7
BG - Bulgaria 7
HR - Croazia 7
SN - Senegal 7
BA - Bosnia-Erzegovina 6
KH - Cambogia 6
Totale 124.792
Salva come PNG Salva come JPEG
Città #
Southend 12.638
Dallas 8.348
Woodbridge 5.122
Ann Arbor 4.000
Ashburn 3.700
Singapore 3.516
San Jose 3.467
Chandler 3.261
Houston 3.035
Council Bluffs 2.700
San Mateo 2.513
Beijing 2.409
Dearborn 1.956
Jacksonville 1.933
Hong Kong 1.830
Falls Church 1.474
Moscow 1.402
Fairfield 1.187
The Dalles 1.158
Seattle 1.069
Cambridge 949
Milan 867
Wilmington 847
Dong Ket 828
Stevenage 762
Portsmouth 694
Hefei 689
Boardman 671
Warsaw 623
Lawrence 611
Rome 602
Los Angeles 599
Ho Chi Minh City 566
Lauterbourg 560
Brooklyn 542
Pisa 473
Ottawa 462
Chicago 443
Santa Clara 407
Hanoi 403
São Paulo 397
New York 336
Buffalo 308
Helsinki 297
Phoenix 271
Tel Aviv 250
Montréal 195
Dublin 189
Old Bridge 185
Salt Lake City 177
San Diego 143
Toronto 139
Naples 121
Figino 119
Montreal 118
Beauharnois 107
Mexico City 105
Redwood City 101
Rio de Janeiro 101
Munich 99
Norwalk 98
Orem 94
London 90
Tampa 90
Johannesburg 86
Tokyo 86
Da Nang 85
Chennai 83
Turin 83
Atlanta 77
Elk Grove Village 74
Bologna 70
Denver 70
Stockholm 68
Haiphong 64
Florence 63
Belo Horizonte 61
Columbus 60
San Francisco 55
Boston 54
Brasília 54
Tashkent 54
Baghdad 51
Frankfurt am Main 51
Dhaka 50
Curitiba 49
Miami 48
Palermo 45
Porto Alegre 45
Guangzhou 44
Bari 43
Hải Dương 42
Seoul 42
Amsterdam 40
Charlotte 40
Fremont 40
Kansas City 40
Washington 40
Augusta 39
Poplar 39
Totale 85.481
Salva come PNG Salva come JPEG
Nome #
N-terminal pro-B-type natriuretic peptide and high-sensitivity troponin T hold diagnostic value in cardiac amyloidosis 1.732
Valutazione delle caratteristiche analitiche e dei risultati clinici di un metodo in chemiluminescenza a cattura di microparticelle (CMIA) per il dosaggio della Galectina-3 sulla piattaforma ARCHITECT 712
[ANMCO/ELAS/SIBioC Consensus document: Recommendations for the use of cardiac biomarkers in heart failure patients] 510
siRNA-mediated targeting of endothelial VWF prevents ET-1 upregulation in porcine aortic endothelial cells chronically exposed to angiotensin II 483
Downregulation of von Willebrand Factor prevents Ang II-induced endothelin-1 expression independently of eNOS activation in porcine endothelial cells 466
Gene silencing of endothelial von Willebrand Factor attenuates angiotensin II-induced endothelin-1 expression in porcine aortic endothelial cells. 419
Cardiac biomarker testing in the clinical laboratory: Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides 388
A chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using quality control sera assayed in an interlaboratory survey 363
State of the art of BNP and NT-proBNP immunoassays: The CardioOrmoCheck study 363
Markers of fibrosis, inflammation, and remodeling pathways in heart failure 350
Inibizione dell'asse ipofiso-gonadale dopo trattamento con un farmaco anabolizzante (Metandrostenolone, Dianabol) 349
Comparison between BNP values measured in capillary blood samples with a POCT method and those measured in plasma venous samples with an automated platform 347
Evaluation of analytical performance of a new high-sensitivity immunoassay for cardiac troponin i 345
125I-Endothelin-1 binding sites in human cardiac tissue 344
Clinical implications of a recent adjustment to the high-sensitivity cardiac troponin T assay: some results. 344
Effect of Coronary Atherosclerosis and Myocardial Ischemia on Plasma Levels of High-Sensitivity Troponin T and NT-proBNP in Patients with Stable Angina 344
Abnormal circulating levels of muscle enzymes and myoglobin in hypothyroidism: their significance and usefulness in follow-up of replacement therapy of the metabolic disorder 339
A new immunoradiometric assay for the measurement of N-terminal fragment of proatrial natriuretic peptide in human plasma: relationship with atrial and brain natriuretic peptides 333
The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicenter study in Italy. 329
A chromatographic method for the determination of uric acid turnover in man 327
N-terminal prob-type natriuretic peptide is a marker of vascular remodelling and subclinical atherosclerosis in asymptomatic hypertensives 320
Evaluation of analytical performance and comparison of clinical results of the new generation method AccuTnI+3 for the measurement of cardiac troponin I using both patients and quality control plasma samples 318
A sensitive and accurate plasma noradrenaline assay using a modified fluorimetric method. 317
Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia 314
A ligand-receptor binding assay of urinary and circulating endogenous digitalis-like factors 313
Valutazione delle caratteristiche analitiche di un nuovo metodo di dosaggio del BNP 313
Evaluation of analytical performance of a novel immunoenzymometric assay for cTnI. 308
A simplified method of measuring free triiodothyronine in serum by conbined equilibrium dialysis and gel Sephadex extraction 305
A chromatographic method for the determination of uric acid turnover in man 301
Acute effects of intravenous amiodarone administration on thyroid function in arrhthmic patients 301
Cardiac biomarker testing in the clinical laboratory:Where do we stand? General overview of the methodology with special emphasis on natriuretic peptides. 301
Forme molecolari della gamma-glutammiltransferasi: caratteristiche e biogenesis. 300
Diagnostic accuracy and prognostic relevance of the measurement of the cardiac natriuretic peptides: a review 298
Natriuretic peptides as biomarkers of cardiac endocrine function in heart failure: New challenges and perspectives 298
Evaluation of the analytical performance of the advanced method for cardiac troponin I for the AxSYM platform: comparison with the old method and the Access system. 297
Direct comparison of B-Type Natriuretic Peptide (BNP) and amino-terminal proBNP in a large population of patients with chronic and symptomatic heart failure: the Valsartan Heart Failure (Val-HeFT) data 292
Evaluation of analytical performance and qualità specifications of a novel immunoenzymometric assay for cTnI: comparison with cTnI and cTnT immunoassays 291
A false positive case of cardiac troponin I: Which diagnostic approach? 288
Usefulness of High-Sensitive Troponin Elevation After Effort Stress to Unveil Vulnerable Myocardium in Patients With Heart Failure 288
Acute effects of intravenous amiodarone administration on thyroid function in arrhthmic patients 285
Acute effects of amiodarone administration on thyroid function in patients with cardiac arrhythmia 285
Marcatori di rimodellamento e fibrosi cardiaca 285
Acute effects of intravenous amiodarone on sulphate metabolites of thyroid hormones in arrhythmic patients 283
A new chemiluminescence immunoassay for CA 15-3, CA 125, CA 19-9: evaluation using QC sera assayed in an interlaboratory survey 282
A simple, sensitive and rapid radioimmunoassay for measurement of urinary albumin 281
Evaluation of reference change values for a hs-cTnI immunoassay using both plasma samples of healthy subjects and patients and quality control samples 281
Comparison of Brain Natriuretic Peptide (BNP) and amino-terminal ProBNP for early diagnosis of heart failure 280
Clinical relevance of non-cardiac determinants of natriuretic peptide levels. 280
A rapid procedure for the quantization of natriuretic peptide RNAs by competitive RT-PCR in congenital heart defects 277
Acute effects of intravenous amiodarone on sulphate metabolite of thyroid hormones in arrhythmic patients 277
Biomarkers of activation of renin-angiotensin-aldosterone system in heart failure: how useful, how feasible? 275
Thirty years of the heart as an endocrine organ: physiological role and clinical utility of cardiac natriuretic hormones 274
N-terminal proB-type natriuretic peptide (NT-proBNP) is superior to BNP for the detection of eraly/mild forms of heart failure 272
Stato dell’arte dell’immunodosaggio dei peptidi natriuretici di tipo B 272
ANMCO/ELAS/SIBioC Consensus Document: Biomarkers in heart failure 271
B-type natriuretic peptide secretion following scuba diving 270
Valutazione esterna di qualità dei peptidi natriuretici BNP e NT-proBNP: risultati del programma Cardioormocheck 270
Hypovitaminosis D in patients with heart failure: effects on functional capacity and patients' survival 266
Evaluation of analytical performance of immunoassay methods for cTnI and cTnT: From theory to practice 266
Measurement of the pro-hormone of brain type natriuretic peptide (proBNP): methodological considerations and pathophysiological relevance 264
Methodological assessment of mitochondrial respiratory chain-enzyme activities in cardiac tissue 263
Criteri per la valutazione delle caratteristiche analitiche e della utilità clinica dei nuovi biomarcatori cardiaci 261
N-terminal fragment of brain natriuretic peptide predicts vascular health and subclinical atherosclerosis: results from MEHLP study 258
Neutrophil gelatinase-associated lipocalin (NGAL) as biomarker of acute kidney injury: a review of the laboratory characteristics and clinical evidences 258
Natriuretic peptides (NPs): Automated electrochemiluminescent immunoassay for N-terminal pro-BNP compared with IRMAs for ANP and BNP in heart failure patients and healthy individuals. 257
The 99th percentile of reference population for cTnI and cTnT assay: Methodology, pathophysiology and clinical implications 257
Evaluation and Comparison with Other High-Sensitivity Methods of Analytical Performance and Measured Values of a New Laboratory Test for Cardiac Troponin I Assay 256
The circulating levels of cardiac natriuretic hormones in healthy adults: effects of age and sex 256
Distribution of plasma cardiac troponin-I values in healthy subjects: pathophysiological considerations 256
Comparison of the Diagnostic Accuracy of Brain Natriuretic Peptide (BNP) and the N-Terminal Part of the Propeptide of BNP Immunoassays in Chronic and Acute Heart Failure: A Systematic Review 256
The combined use of neutrophil gelatinase-associated lipocalin and brain natriuretic peptide improves risk stratification in pediatric cardiac surgery 256
State of the art of aldosterone immunoassays. A multicenter collaborative study on the behalf of the Cardiovascular Biomarkers Study Group of the Italian Section of European Society of Ligand Assay (ELAS) and Società Italiana di Biochimica Clinica (SIBIOC). 254
Evaluation of analytical performances using standardized analytical protocols and comparison of clinical results of the new ADVIA BNP and NT-proBNP immunoassays for the Centaur XPT platform 254
Influence of gender on circulating cardiac natriuretic hormones in patients with heart failure. 253
Rilevanza clinica e interpretazione dei marcatori biochimici nello scompenso cardiaco 253
Analytical performance and diagnostic accuracy of a fully-automated electrochemiluminescent assay of the N-terminal fragment of brain natriuretic peptide in patients with cardiomyopathy: comparison with immunoradiometric assay methods for brain natriuretic peptide and atrial natriuretic peptide. 251
Natriuretic peptide testing in primary care patients. 251
Prognostic value of combined use of B-ype natriuretic peptides and interleukine-6 in predicting cardiac mortalità in end-stage renal disease patients 249
S-nitrosoglutathione as a substrate of gamma-glutamyltransferase (GGT)- A kinetic study 247
Evaluation of the analytical performance of a new ADVIA immunoassay using the Centaur XPT platform system for the measurement of cardiac troponin i 246
No variation in Hsp70 mRNA level during cardiac surgery in pediatric patients evaluated by semiquantitative RT-PCR 245
Cheyne-Stokes respiration is associated with neurohormonal activation in patients with heart failure 245
Comparison of two BNP immunoassays using the same antibodies and standard materials 245
Analytical performance and clinical results of a fully automated MEIA system for brain natriuretic peptide assay: comparison with a point of care testing method 245
BNP values in the first days of life measured with an automated immunoassay platform 243
Genomic medicine and thrombotic risk: who, when, how and why? 243
Plasma gamma-glutamyltransferase fractions: diagnostic and prognostic predictive value 243
Proposta per l’utilizzo in Pronto Soccorso delle troponine cardiache misurate con metodi di ultima generazione in pazienti con sospetto di sindrome coronarica acuta senza sopraslivellamento del tratto ST 243
Cardiac troponins as biomarkers for cardiac disease 243
Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications 242
C-type natriuretic peptide expression in patients with chronic heart failure: effects of aerobic training. 240
New biomarkers for risk stratifications in patients with heart failure: high-sensitivity troponin I and galectin-3 240
Detection of mtDNA with 4977 bp deletion in blood cells and atherosclerotic lesions of patients with coronary artery disease. 240
Deoxyribonucleic acid damage in human lymphocytes after percutaneous transluminal coronary angioplasty 239
Prognostic complexity of heart failure and network analysis: the holistic risk stratification 239
Diagnosis of preclinical /mild heart failure with B-type natriuretic peptides: compariosn betwwen BNP and NT-proBNP immunoassay methods 238
Gamma-glumamyl-transferase levels are associated with inflammatory activation, myocardial dysfunction and mortality in pateints with ST-elevation myocardial infarction 237
B-type plasma natriuretic hormone level in operated Fallot patients 236
New and emerging biomarkers of heart failure 235
Risk factors and prognostic value of daytime Cheyne-Stokes respiration in chronic heart failure patients 234
Totale 30.653
Salva come PNG Salva come JPEG
Categoria #
all - tutte 612.408
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 612.408
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20225.872 0 0 0 966 62 55 887 1.779 511 924 56 632
2022/20236.603 616 117 70 1.176 1.151 1.248 12 531 1.101 143 267 171
2023/20241.761 370 85 290 104 72 276 232 72 25 47 29 159
2024/202516.831 116 65 1.084 346 275 1.163 2.348 5.046 1.570 1.069 2.463 1.286
2025/202636.457 1.629 7.932 3.339 3.207 3.369 2.012 6.125 1.660 1.684 2.521 940 2.039
2026/20278.857 631 1.598 3.022 3.606 0 0 0 0 0 0 0 0
Totale 125.144